the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
Published 1 year ago • 124 plays • Length 0:30Download video MP4
Download video MP3
Similar videos
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
0:52
patient eligibility in the ameera-6 trial of amcenestrant
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
26:34
cdk 4/6 inhibitors in breast cancer advanced and adjuvant settings
-
7:50
❝乳癌藥物認知 8❞ 轉移性乳癌治療 - 標靶藥cdk4/6抑制劑-abemaciclib
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
0:53
final results of the phase 3 data trial assessing aromatase inhibition in hr breast cancer
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
3:44
breast cancer breakthroughs: treatment gap filled by the emerald clinical trial
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
1:03
azd2014 for treating er metastatic breast cancer – mode of action and trial results
-
7:26
s1222 hr , stage iv breast cancer: fulvestrant w/wo everolimus /- anastrozole
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
3:38
emerald-1 trial in hcc
-
1:47
an overview of the ma17r trial in breast cancer
-
16:10
emerald study lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. aditya bardia
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use